Status | Study |
Recruiting |
Study Name: Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older Condition: Common Variable Immune Deficiency Specific Antibody Deficiency Date: 2016-10-03 Interventions: Biological: Zostavax® Zostavax® immunization |
Withdrawn |
Study Name: Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID) Condition: Granulomatous and Lymphocytic Interstitial Lung Disease Date: 2016-05-16 Interventions: Drug: Rituximab (RTX) and Azathioprine (AZA) |
Not yet recruiting |
Study Name: Improving the Diagnosis of Common Variable Immune Deficiency Condition: Common Variable Immune Deficiency (CVID) Date: 2016-02-08 |
Not yet recruiting |
Study Name: Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial Condition: Rhinovirus Infection Date: 2016-01-13 Interventions: Drug: pegylated interferon alfa 2 Other: P |
Recruiting |
Study Name: Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies Condition: Primary T-cell Immunodeficiency Disorders Common Variable Immunodefici Date: 2015-10-16 Interventions: Drug: Immunosuppression Only Conditioning |
Completed |
Study Name: Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease Condition: Immune Deficiency, Antibody Date: 2015-08-31 Interventions: Other: questionnaire survey The HR-QOL PIDD survey will be administered to the patient by the site PI or |
Completed |
Study Name: A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Condition: Primary Antibody Deficiency. Date: 2014-09-02 Interventions: Biological: Subgam® (Human Normal Immunoglobulin Solution) |
Recruiting |
Study Name: Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency Condition: CVID Enteropathy Chronic Diarrhea Date: 2014-07-23 Interventions: Biological: Ustekinumab Ustekinumab is an IL-12 and IL-23 antagonist biologic drug that is FDA approved |
Completed |
Study Name: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2013-09-13 Interventions: Biological: Gammaplex (5%) Biological: Gam |
Completed |
Study Name: The Rifaximin Study in CVID Condition: Common Variable Immunodeficiency (CVID) Date: 2013-09-12 Interventions: Drug: Rifaximin Other Name: Xifaxan |